Raising the BD bar

Innovator biotechs say that the business development bar has been raised for companies developing new modalities, with potential partners seeking proof of mechanism on top of proof of efficacy.

A host of products based on new modalities is likely to come to market in the next few years, with at least 40 in Phase III testing or registrational studies (see “A Pathway to BioPharma 3.0”)...